8-K Announcements
6Material company update
May 11, 2026·SEC
Material company update
Mar 27, 2026·SEC
Material company update
Mar 24, 2026·SEC
Harrow Health, Inc.(HROW)Earnings, Financials & Key Ratios
HROW•NASDAQ
$46.15
Price updated Jul 7, 2026
AboutHarrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in San Diego, California.Show more
- Revenue$272M+36.4%
- EBITDA$58M+162.9%
- Net Income-$5M+70.6%
- EPS (Diluted)-0.14+71.4%
- Gross Margin75.05%-0.4%
- EBITDA Margin21.12%+92.7%
- Operating Margin14.18%+220.8%
- Net Margin-1.89%+78.5%
- ROE-8.47%+66.3%
HROW Price & Volume
Harrow Health, Inc. (HROW) stock price & volume — 10-year historical chart
Loading chart...
Volatile Revenue Growth Masks Deepening Operational Losses
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Excessive debt and dilution
Key Thesis Takeaways
- Harrow Health faces a challenging transition as its aggressive, acquisition-led growth strategy struggles to achieve sustainable profitability, evidenced by a sharp 7.6% revenue contraction in 2026Q1.
- The company's reliance on debt financing has escalated significantly, with the debt-to-equity ratio reaching 10.61, creating substantial pressure on long-term financial flexibility.
- Investors should monitor the firm's ability to stabilize its ophthalmic pharmaceutical portfolio and reverse the current trend of negative operating margins, which plummeted to -50.0% in the most recent quarter.
Verdict Logic
the company's inability to maintain consistent profitability is highlighted by a -50.0% operating margin and a concerning reliance on debt, evidenced by a 10.61 debt-to-equity ratio.
HROW Growth Metrics
Harrow Health, Inc. (HROW) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years39.56%
5 Years40.99%
3 Years45.39%
TTM26.22%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM31.04%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM33.8%
Return on Capital
10 Years-19.92%
5 Years4.06%
3 Years5.41%
Last Year12.85%
HROW Recent Earnings
Harrow Health, Inc. (HROW) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 3/12 qtrs (25%)●Beat Revenue 1/12 qtrs (8%)
Q2 2026Latest
May 11, 2026Metric
Actual
Est
EPS
$0.63-46.5%
$0.43
Rev
$44M-15.7%
$52M
Q2 2026
Mar 2, 2026Metric
Actual
Est
EPS
$0.26-35.0%
$0.40
Rev
$89M-1.0%
$90M
Q4 2025
Nov 10, 2025Metric
Actual
Est
EPS
$0.33+50.0%
$0.22
Rev
$72M-18.6%
$88M
Q3 2025
Aug 11, 2025Metric
Actual
Est
EPS
$0.24-23.4%
$0.31
Rev
$64M-13.8%
$74M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 11, 2026 | $0.63vs $0.43-46.5% | $44Mvs $52M-15.7% |
| Q2 2026 | Mar 2, 2026 | $0.26vs $0.40-35.0% | $89Mvs $90M-1.0% |
| Q4 2025 | Nov 10, 2025 | $0.33vs $0.22+50.0% | $72Mvs $88M-18.6% |
| Q3 2025 | Aug 11, 2025 | $0.24vs $0.31-23.4% | $64Mvs $74M-13.8% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Harrow Health, Inc. (HROW)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $46.15 | $1.72B | -329.64 | 36.41% | -1.89% | -8.47% | — | |
| $33.12 | $1.34B | 27.83 | 27.37% | 6.35% | 29.49% | — | |
| $40.09 | $8.23B | -14.47 | — | — | -68.16% | — | |
| $123.77 | $9.1B | -21.16 | — | — | -42.78% | — | |
| $5.35 | $291.09M | -7.23 | -3.13% | -46.83% | -59.1% | — | |
| $155.37 | $3.88B | 5284.69 | -6.38% | 2.15% | 2.19% | — |
Compare HROW vs Peers
Harrow Health, Inc. (HROW) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
HROW SEC Filings & Documents
Harrow Health, Inc. (HROW) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when HROW posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
HROW Frequently Asked Questions
Harrow Health, Inc. (HROW) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Harrow Health, Inc.'s revenue?
Harrow Health, Inc. (HROW) reported $268.7M in revenue for fiscal year 2025.
How fast is Harrow Health, Inc. growing?
Harrow Health, Inc. (HROW) grew revenue by 36.4% over the past year. This is strong growth.
Is HROW profitable?
Harrow Health, Inc. (HROW) reported a net loss of $15.0M for fiscal year 2025.
Dividend & Returns
What is HROW's return on equity?
Harrow Health, Inc. (HROW) has a return on equity (ROE) of -8.5%. Negative ROE indicates the company is unprofitable.
What is Harrow Health, Inc.'s free cash flow?
Harrow Health, Inc. (HROW) generated $14.3M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.